Arvinas Inc
ARVN13.480USD
+0.520+4.01%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
954.38MValor de mercado
PerdaP/L TTM
Mais detalhes de Arvinas Inc Empresa
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Informações de Arvinas Inc
Código da empresaARVN
Nome da EmpresaArvinas Inc
Data de listagemSep 27, 2018
CEODr. John G. Houston, Ph.D.
Número de funcionários430
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 27
Endereço5 Science Park
CidadeNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06511-1966
Telefone12035351456
Sitehttps://www.arvinas.com/
Código da empresaARVN
Data de listagemSep 27, 2018
CEODr. John G. Houston, Ph.D.
Executivos da empresa Arvinas Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 5 de fev
Atualizado em: qui, 5 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Outro
66.13%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Outro
66.13%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.71%
Hedge Fund
26.23%
Investment Advisor/Hedge Fund
21.31%
Venture Capital
6.56%
Corporation
5.38%
Research Firm
4.23%
Individual Investor
2.59%
Pension Fund
0.53%
Bank and Trust
0.31%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
513
61.93M
168.36%
-2.99M
2025Q3
525
64.92M
150.53%
-4.18M
2025Q2
518
67.55M
122.76%
+4.71M
2025Q1
504
63.19M
117.99%
-22.92M
2024Q4
484
75.18M
115.79%
+228.04K
2024Q3
476
75.20M
114.63%
+1.35M
2024Q2
469
73.21M
109.58%
+2.16M
2024Q1
476
70.86M
103.71%
+13.21K
2023Q4
483
66.87M
80.36%
+15.93M
2023Q3
458
50.77M
99.64%
+2.00M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.55M
13.31%
-831.93K
-8.87%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.17M
8.05%
-87.00K
-1.65%
Sep 30, 2025
Pfizer Inc
3.46M
5.38%
--
--
Sep 30, 2025
D. E. Shaw & Co., L.P.
3.41M
5.3%
+57.86K
+1.73%
Nov 06, 2025
Logos Global Management LP
2.50M
3.89%
-3.08M
-55.16%
Oct 14, 2025
Millennium Management LLC
2.13M
3.32%
+233.48K
+12.30%
Sep 30, 2025
State Street Investment Management (US)
1.87M
2.92%
+140.76K
+8.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.67M
2.6%
+85.09K
+5.37%
Sep 30, 2025
TCG Crossover Management, LLC
1.62M
2.52%
+1.62M
--
Sep 30, 2025
New Leaf Venture Partners LLC
1.59M
2.47%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.76%
State Street SPDR S&P Pharmaceuticals ETF
1.65%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares U.S. Pharmaceuticals ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.24%
Zacks Small/Mid Cap ETF
0.22%
iShares Health Innovation Active ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.1%
Ver Mais
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.76%
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.65%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.91%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.7%
iShares U.S. Pharmaceuticals ETF
Proporção0.28%
Federated Hermes MDT Small Cap Core ETF
Proporção0.24%
Zacks Small/Mid Cap ETF
Proporção0.22%
iShares Health Innovation Active ETF
Proporção0.16%
ProShares Ultra Nasdaq Biotechnology
Proporção0.11%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.1%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
